The TetraKit Platform: Rapid and high-yielding radiolabeling of any cancer-targeting biomolecule for accelerated radiopharmaceutical development
The TetraKit Platform uses proprietary radiolabeling via the tetrazine ligation, the fastest small-molecule click chemistry. Radiolabeled tetrazines are clicked onto cancer-targeting precursors and act as unique “one-fits-all” building blocks, making it easy to switch between radionuclides for seamless theranostics. The TetraKit Platform employs linkers that guide and fine-tune biodistribution and excretion pathways, optimizing therapeutic efficacy.
The TetraKit Platform uses preformed tetrazines to label any biomolecule with therapeutic or diagnostic radionuclides.
The TetraKit Platform outperforms conventional radiohalogenation
Radiohalogens represent the most promising single class of radionuclides for therapy and diagnostic imaging; including astatine-211 for alpha therapy, iodine-131 for beta therapy, fluorine-18 for PET imaging and iodine-123 for SPECT imaging. But conventional radiohalogens is cumbersome and in some cases not possible. The TetraKit Platform introduces efficient radiohalogenation for any biomolecule, making it as straightforward as the “shake-and-bake” methods known for radiometals. Its “plug-and-play” properties enable rapid labeling of diverse biomolecules, including peptides, nanobodies, antibodies, proteins and oligonucleotides. Importantly, it requires only microgram quantities of precursor, enabling microdosing and maximizing adaptability for a wide range of radiopharmaceutical development. In addition, the TetraKit Platform is also compatible with commonly used radiometals.
-
The TetraKit Platform provides unique manufacture and scaling possibilities
The unique TetraKit Platform redefines radiopharmaceutical manufacture by using pre-formed radiolabeled tetrazines. A single batch of these tetrazines can produce a library of radiopharmaceuticals at a centralized facility, or alternatively be shipped to clinical centers for on-site preparation of the final compound via simple click chemistry, with minimal training necessary. This reduces the need for dedicated equipment and consumables, as well is lengthy and expensive optimization of radiosynthesis for each specific radiopharmaceutical. With the TetraKit Platform, this is concentrated in a single compound, the tetrazine one-fits-all building block. The kit-based approach ensures easy implementation in radiopharmacies. TetraKit Technologies is developing the commercial consumables needed, such as GMP-grade precursors, cassettes and cold kits, and automated methods for commercial modules, to enable tech transfer and establishment at any radiopharmacy.
-
The TetraKit Platform enables next-generation theranostics
Theranostics is a powerful emerging concept within nuclear medicine, and especially oncology. It combines radioligand therapy with imaging-based diagnostics, relying on complementary pairs of radiopharmaceutical. In theranostics, the same targeting vector is labeled with radionuclides, that are either therapeutic or diagnostic, and sometimes both. Theranostics is therefore ideal for diagnosing, treating and monitoring metastatic cancer, offering solutions where chemotherapy fails and even potential as first-line treatment. The TetraKit Platform enables the seamless switching between alpha- and beta-emitting therapeutic radionuclides with PET and SPECT diagnostics on the same molecule, enabling the full spectrum of theranostic applications.
